No Detail Found!

The Pattern of Pharmacovigilance Reports of Antibiotics Submitted to the Iraqi Pharmacovigilance Center before and After Covid-19

Author(s)
Ahmed Mohammed Al-Nahrain University- College of Pharmacy,Baghdad,Iraq
Mohammed Murtadha Al-Nahrain University- College of Pharmacy,Baghdad,Iraq
Manal Mohammed Younus MOH Iraqi PV Centre,Baghdad,Iraq
Abstract
Introduction antibiotics had been heavily used in the COVID-19 period naturally leading to increase the occurrence of adverse drug reactions. Objectives To assess the changing reporting pattern 6 months before and after the first case of COVID-19 in Iraq. Methods A retrospective analysis of the data reported to the Iraqi Centre of Pharmacovigilance was conducted to assess if any change in the pattern of the reported antibiotics has occurred among different antibiotics for the period from Sep 2019 till Sep 2020. Descriptive statistics were conducted for data analysis, and the chi-square test has been utilized to assess differences in ADR severity between the comparative groups. Results The majority of patients were aged 18-44, with a slight increase in the 45-64 age group in 2020. A shifted has been seen from ceftriaxone in the first 6 months to azithromycin in the second 6 months. Gastrointestinal disorders emerged as the most common ADR in 2020, while skin and subcutaneous tissue reactions predominated in 2019. A significant increase in serious ADRs was observed in 2020 compared to 2019. Conclusion This study focused the attention on the dynamic nature of antimicrobial use and ADRs profiles. The increased prevalence of serious ADRs 6 months after COVID19 underlines the need for more governmental and non- governmental support to the Iraqi Centre of Pharmacovigilance to implement antibiotic stewardship programs to minimize the risk of AB ADRs.
Publication Details
Page(s) 9158-9164
Published Journal: Pakistan Journal of Life and Social Sciences, Volume: 23, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
Antibiotics Pharmacovigilance COVID-19 Adverse Drug Reactions ADRs
References
Magiorakos A. P.,Srinivasan A.,Carey R. B.,Carmeli Y.,Falagas M. E.,Giske C. G.,Perl T. M. .2012 .Multidrug-resistant, extensively drug-resistant and pan-resistant bacteria: an urgent threat to one and all. Clinical Microbiology and Infection, 18(3) : 268-281.
Sandes V.,Figueras A.,Lima E.C. .2024 .Pharmacovigilance Strategies to Address Resistance to AB and Inappropriate Use-A Narrative Review. AB, 13 : .
De Gregorio E.,Di Pierro F.,Indiveri F.,Di Rosa F. .2016 .Antibiotic-associated diarrhea: Epidemiology, microbiology, and management strategies. World journal of gastroenterology, 22(15) : 3573.
Lazaridou E.,Papapetropoulou M.,Falagas M. E. .2015 .Underreporting of adverse drug reactions: a continuing challenge. Therapeutic advances in drug safety, 6(1) : 1-11.
Benson K.,Ryan P.,Lippi G. .2018 .Real-world data and pharmacovigilance: opportunities and challenges. Clinical Pharmacology & Therapeutics, 103(3) : 326-330.
Chen Y.,Zeng D.,Liu Y.,X. Y. .2018 .Application of machine learning in pharmacovigilance: a systematic review. Drug Safety, 41(1) : 1-17.
World Health Organization (WHO). ,May 19 .2020 .. Strategy Update. document (WHA73, : .
World Health Organization. .2020 .Antibiotic use during the COVID-19 pandemic: global guidance. World Health Organization., : .
. .Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. , : .
Tacconelli E.,Carrara E.,Luca V.,Pompei F.,Ricciardi G.,Mensa S. .2020 .Antibiotic consumption in 2020: a global challenge in the COVID-19 era. Clinical Microbiology and Infection, 26(4) : 459-460.
World Health Organization. .2022 .Antimicrobial resistance. World Health Organization., : .
. .Inadequate use of AB in the covid-19 era: effectiveness of antibiotic therapy bmcinfectdis. , : .
Lazaridou E.,Papapetropoulou M.,Falagas M. E. .2015 .Underreporting of adverse drug reactions: a continuing challenge. Therapeutic advances in drug safety, 6(1) : 1-11.
Benson K.,Ryan P.,Lippi G. .2018 .Real-world data and pharmacovigilance: opportunities and challenges. Clinical Pharmacology & Therapeutics, 103(3) : 326-330.
Lepak N. J. .2018 .Antimicrobial prescribing patterns in primary care: A systematic review. JAMA Internal Medicine, 178(7) : 940-949.
World Health Organization. .2020 .Coronavirus disease (COVID-19) pandemic. , : .
Gaudreault F. .2020 .Azithromycin for the treatment of COVID-19: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 75(9) : 2653-2662.
Wang M. .2020 .Remdesivir and chloroquine potentially inhibit the novel coronavirus (2019- nCoV) through binding to its RNA-dependent RNA polymerase. Cell Research, 30(3) : 269-274.
Patel N.,Desai N. .2018 .Adverse drug reactions: An overview. Indian Journal of Pharmaceutical Education and Research, 52(2) : 118-127.
Lippi G. .2020 .The COVID-19 pandemic and adverse drug reactions: A call for action. Clinical Pharmacology & Therapeutics, 107(5) : 1013-1015.
0

Citations

0

Downloads

37

Views